Clinical Trials
Optimi Health Completes First Psilocybin Export to UK for Phase 2 Trial
Optimi Health Corp. has exported naturally derived psilocybin to the UK for a planned Phase 2 clinical trial, marking a milestone in international psychedelic drug distribution.
Carmed Pharmaceuticals Publishes Second Peer-Reviewed Study of Its Carvacrol-Based Formulations
Carmed Pharmaceuticals highlights a new peer-reviewed study on its formulations Vacrol® and S-Mix® in the journal Antioxidants, underscoring its commitment to scientific research as it expands into the U.S. market.
Quantum BioPharma Completes Phase 1 Trial for Multiple Sclerosis Therapy Lucid-MS
Quantum BioPharma announces completion of Phase 1 clinical studies for Lucid-MS, a therapy targeting myelin repair in multiple sclerosis, and submission of an IND application to the FDA.
Radioactive Collagen Tiles Reduce Brain Cancer Recurrence in Clinical Trial
A clinical trial found that placing radioactive collagen tiles into the brain cavity during tumor removal dramatically cuts recurrence and extends survival, offering new hope for brain cancer treatment.
Regentis Biomaterials Set to Begin European Surgeon Training for GelrinC Cartilage Implant
Regentis Biomaterials plans to commence surgeon training activities in Q3 2026 to support the commercial rollout of its CE Mark-approved GelrinC treatment for knee cartilage lesions, addressing a significant unmet need in Europe.
Quantum BioPharma Advances Multiple Sclerosis Therapy with LUCID-MS Program, Completes Phase 1 Trials
Quantum BioPharma has completed Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and filed an IND with the FDA, addressing the critical unmet need for neuroprotective treatments.
CNS Pharmaceuticals Secures Oversubscribed $22.5 Million Financing to Fuel Growth Strategy
CNS Pharmaceuticals highlights its oversubscribed $22.5 million financing and strategic reset in a virtual investor presentation, positioning the company to pursue transformational opportunities and create shareholder value.
TransCode Therapeutics to Host R&D Webcast as It Advances Phase 2a Trial for Colorectal Cancer
TransCode Therapeutics will provide strategic and clinical updates during its first live R&D webcast, anchored by its Phase 2a trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer, highlighting progress in RNA-based oncology treatments.
Oncotelic Therapeutics to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026
Oncotelic Therapeutics will present its proprietary PDAOAI platform at Qdrant Vector Space Day 2026, highlighting how it accelerated two drug candidates from concept to investigational new drug filings in under two years, significantly reducing time and cost.
Lifordi Immunotherapeutics Reports Positive Phase 1 Data for LFD-200 in Autoimmune Disease
Phase 1 data for LFD-200, a subcutaneous glucocorticoid antibody-drug conjugate, shows anti-inflammatory activity without systemic steroid toxicity, with patient dosing ongoing in rheumatoid arthritis.
HighTide Therapeutics Unveils New Data Supporting HTD1801's Renoprotective Effects at ERA 2026
New findings from HighTide Therapeutics show that its lead candidate HTD1801 protects kidney function by targeting podocyte inflammation and apoptosis, offering potential as a disease-modifying therapy for chronic kidney disease.
NeuroThera Labs Acquires Majority Stake in CliniQuantum, Merging Quantum Computing with Clinical Trials
NeuroThera Labs Inc. has closed its acquisition of a 54.01% stake in CliniQuantum Ltd., aiming to enhance clinical trial precision through quantum simulation and Monte Carlo methods.
Quantum BioPharma Builds Diversified Pipeline Targeting Neurological and Wellness Markets
Quantum BioPharma Ltd. advances LUCID-MS for multiple sclerosis and expands into alcohol metabolism with unbuzzd, addressing unmet needs in neurology and wellness.
Oncotelic Therapeutics Expands Sapu003 Phase 1b Program with Global CRO Appointment, Signaling Shift to Multinational Development
Oncotelic Therapeutics and Sapu Nano expand the Phase 1b trial for Sapu003, appointing Global Clinical Trials to lead international execution, marking a transition from an Australia-based study to a multinational strategy.
TransCode Therapeutics Reports Positive Phase 1a Results for TTX-MC138, Paving Way for Phase 2a Trial
TransCode Therapeutics announced positive Phase 1a results for its investigational microRNA-10b inhibitor TTX-MC138, showing durable disease stabilization and no dose-limiting toxicities, supporting advancement to Phase 2a clinical development.
New Pill Daraxonrasib Shows Promise in Doubling Survival for Pancreatic Cancer Patients
Revolution Medicines' daraxonrasib, targeting the KRAS gene, has reportedly doubled survival in early pancreatic cancer trials, offering cautious hope for a disease with limited treatment options.
Lexaria Bioscience to Attend BIO International Convention Amid Record Business Development Interest
Lexaria Bioscience Corp. announces its attendance at the BIO International Convention in San Diego, highlighting a surge in partnership interest for its DehydraTECH drug delivery platform, which could lead to significant collaborations with pharmaceutical giants and biotech firms.
American Heart Association Launches First-Ever Heart Transplant Research Network to Address Innovation Gaps and Inequities
The American Heart Association's new research network, involving 14 centers and a coordinating center, aims to modernize heart transplant care by improving data infrastructure, advancing research, and standardizing quality care to address long-standing disparities and innovation gaps.
Viromed Medical AG Completes Study on Cold Plasma Application in the Lung, Shows Promise for Treating Ventilator-Associated Pneumonia
Viromed Medical AG announces successful completion of a multi-year study on cold atmospheric plasma in the lung, demonstrating potential as a non-pharmacological treatment for severe infectious lung diseases, with first successful patient applications already achieved.
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate Lucid-MS and Commercial Product unbuzzd™
Quantum BioPharma's lead drug Lucid-MS targets nerve damage in multiple sclerosis, with a Phase 2 trial upcoming, while its alcohol metabolism product unbuzzd™ generates royalty revenue.
Regentis Biomaterials Targets $3 Billion U.S. Knee Cartilage Repair Market with Novel Off-the-Shelf Solution
Regentis Biomaterials' GelrinC platform offers a potential first-in-class, ready-to-use knee cartilage repair treatment with superior pain relief and faster recovery, advancing through U.S. Phase III trials.
Lantern Pharma Reports Phase 2 HARMONIC Trial Data Showing LP-300 Benefit in EGFR-Mutant Lung Cancer
Lantern Pharma announced updated Phase 2 data for LP-300 in EGFR L858R-mutant non-small cell lung cancer, showing improved progression-free survival and a clean safety profile, with an FDA-cleared protocol amendment extending dosing to eight cycles.
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities in BioMedWire Podcast
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on The BioMedWire Podcast, where co-founder Anthony Durkacz discussed the company's lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd, emphasizing upcoming Phase 2 trials and revenue potential.
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Potential in BioMedWire Podcast
Quantum BioPharma's co-founder discusses the unmet need in multiple sclerosis treatment with Lucid-MS and the commercial potential of unbuzzd, as the company prepares for a Phase 2 trial.
Regentis Biomaterials Nears Key Milestones for Simplified Cartilage Repair Implant
Regentis Biomaterials advances GelrinC, a single-step hydrogel implant for knee cartilage repair, targeting a $3 billion U.S. market with CE Mark approval and a Phase III trial over 50% enrolled.
Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Key Clinical Milestones
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions, will participate in a fireside chat at the Jefferies Global Healthcare Conference, highlighting its Phase 3 and Phase 2 programs for major depressive disorder and generalized anxiety disorder.
Regentis Biomaterials Advances Toward Key Milestones for Simplified Cartilage Repair Platform
Regentis Biomaterials Ltd. is progressing its GelrinC hydrogel implant toward European commercialization and U.S. FDA submission, targeting a $3 billion market for knee cartilage repair with a cell-free, single-step procedure.
Optimi Health Welcomes Australia's TGA Framework Update, Expanding Psychedelic Therapy Access
Optimi Health Corp. highlights Australia's updated TGA framework for psilocybin and MDMA, which broadens therapy teams and treatment settings, potentially accelerating adoption of psychedelic-assisted therapy.
Regentis Biomaterials Targets $3 Billion Knee Cartilage Repair Market with Off-the-Shelf GelrinC Platform
Regentis Biomaterials’ GelrinC platform shows promise as a first-in-class, off-the-shelf solution for knee cartilage repair, with clinical data indicating approximately 100% greater pain improvement versus microfracture and a clear path to U.S. market entry.
Quantum BioPharma Advances Multiple Sclerosis Program with Differentiated Approach
Quantum BioPharma is progressing its clinical-stage multiple sclerosis program targeting demyelination, a novel strategy distinct from immune-modulating therapies, while maintaining a diversified portfolio including consumer wellness products and sufficient capital through 2028.